Post-Operative Nausea And Vomiting Study In Female Patients
Post-Operative Nausea And Vomiting Study In Female Patients
The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic
 medication to prevent nausea and vomiting in females after surgery.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study
 to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50 mg or 150 mg) for Three
 Consecutive Days When Administered with a Single Intravenous Dose of Ondansetron
 Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge
 Nausea and Vomiting in Female Subjects with Known Risk Factors for Post-operative Nausea and
 Vomiting Who are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an
 Increased Emetogenic Risk
Inclusion Criteria:

 -  Known, specified risk factors for PONV (post operative nausea and vomiting)

 -  Undergoing gynecologic or gallbladder surgery.

 Exclusion Criteria:

 -  pregnant or breastfeeding

 -  post-menopausal